Leishmania Braziliensis: Report of a Pediatric Imported Case With Response to Liposomal Amphotericin B

Campos-Muñoz, Lucía; Quesada-Cortés, Alicia; Martín-Díaz, M.A.; Rubio-Flores, C.; Lucas-Laguna, R. de

doi:10.1016/s1578-2190(07)70388-8

Cited by 4 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found three case reports of children infected by Leishmania (Viannia) braziliensis treated with amphotericin deoxycholate whose CL lesions were cured without adverse effects 46,47 . In contrast, VL treatment with liposomal amphotericin showed no difference in effi cacy or safety between children and adults 18 .…”

Section: Resultsmentioning

confidence: 99%

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Silva

Galvão

Gomes

et al. 2013

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Revista da Sociedade Brasileira de Medicina Tropical 46(6):669-677, Nov-Dec, 2013http://dx.doi. org/10.1590/0037-8682-0104-2013 Address to: Dr a Juliana Saboia Fontenele e Silva. Lab. ABSTRACT We aimed to assess and synthesize the information available in the literature regarding the treatment of American tegumentary leishmaniasis in special populations. We searched MEDLINE (via PubMed), EMBASE, LILACS, SciELO, Scopus, Cochrane Library and mRCT databases to identify clinical trials and observational studies that assessed the pharmacological treatment of the following groups of patients: pregnant women, nursing mothers, children, the elderly, individuals with chronic diseases and individuals with suppressed immune systems. The quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The available evidence suggests that the treatments of choice for each population or disease entity are as follows: nursing mothers and children (meglumine antimoniate or pentamidine), patients with renal disease (amphotericin B or miltefosine), patients with heart disease (amphotericin B, miltefosine or pentamidine), immunosuppressed patients (liposomal amphotericin), the elderly (meglumine antimoniate), pregnant women (amphotericin B) and patients with liver disease (no evidence available). The quality of evidence is low or very low for all groups. Accurate controlled studies are required to fi ll in the gaps in evidence for treatment in special populations. Post-marketing surveillance programs could also collect relevant information to guide treatment decision-making.

show abstract

Section: Resultsmentioning

confidence: 99%

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Silva

Galvão

Gomes

et al. 2013

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…Management strategy was described in 603 patients: 521 (86.4%) received systemic treatment, 42 (7.0%) local treatment, 6 (1.0%) combined local and systemic treatment and 34 (5.6%) no treatment (Table 7). A total of 85 failures or relapses were reported, representing 14.1% of cases [20,30,69,77,82,92,96,97,100,116,120,121,125,126,128,129,139,140,146,150,165,173,[177][178][179][180]194,228,269]. When retreatment was described (n = 44, [30,82,92,96,97,100,116,120,121,125,126,128,129,139,140,146,150,173,177-180, 194,228,269]), it most often consisted of a different strategy and/or drug (92.3%, [30,82,92,96,97,100,116,120,121,125,126,128,129,139,140,146,…”

Section: Clinical Aspects and Management Of Cutaneous Leishmaniasismentioning

confidence: 99%

Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021—A Comprehensive Review

Rocha¹,

Pereira

Maia³

2022

Pathogens

View full text Add to dashboard Cite

Leishmaniases are human and animal parasitic diseases transmitted by phlebotomine sand flies. Globalization is an important driver of the burden and in the current dynamics of these diseases. A systematic review of articles published between 2000 and 2021 was conducted using the PubMed search engine to identify the epidemiology and clinical management of imported human leishmaniases as a fundamental step to better manage individual cases and traveler and migrant health from a global perspective. A total of 275 articles were selected, representing 10,341 human imported cases. Identified drivers of changing patterns in epidemiology include conflict and war, as well as host factors, such as immunosuppression, natural and iatrogenic. Leishmania species diversity associated with different clinical presentations implies diagnostic and treatment strategies often complex to select and apply, especially in non-endemic settings. Thus, diagnostic and management algorithms for medical clinical decision support are proposed. Increased surveillance of non-endemic cases, whether in vulnerable populations such as refugees/migrants and immunocompromised individuals or travelers, could improve individual health and mitigate the public health risk of introducing Leishmania species into new areas.

show abstract

“…44 Liposomal amphotericin B has been used anecdotally in the treatment of cutaneous and mucocutaneous disease caused by L. V. braziliensis acquired in Belize, Bolivia, Peru, and Brazil as well as in immunocompromised patients. 19,24,[26][27][28][29]59 A prospective, non-randomized study comparing liposomal amphotericin B with sodium stibogluconate for treatment of CL caused by L. V. braziliensis found no failures in the liposomal amphotericin B-treated group and fewer side effects. 19 Successful use of liposomal amphotericin B in the treatment of VL, however, does not necessarily extrapolate to cutaneous disease, because the pharmacokinetics of liposomal amphotericin B in cutaneous disease have not been well-established.…”

Section: -56mentioning

confidence: 99%

A Species-Specific Approach to the Use of Non-Antimony Treatments for Cutaneous Leishmaniasis

Ramanathan

Talaat

Fedorko

et al. 2011

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

We used a species-specific approach to treat 10 patients with cutaneous leishmaniasis diagnosed using polymerase chain reaction. Non-antimony treatments (oral miltefosine, ketoconazole, and liposomal amphotericin B) were chosen as an alternative to pentavalent antimony drugs based on likely or proven drug efficacy against the infecting species. Leishmania Viannia panamensis was diagnosed in three patients and treated successfully with oral ketoconazole. Miltefosine treatment cured two patients with L. infantum chagasi. A wide variety of Leishmania responded to liposomal amphotericin B administered for 5–7 days. Three patients with L. V. braziliensis, one patient with L. tropica, and two patients with L. infantum chagasi were treated successfully. One person with L. V. braziliensis healed slowly because of a resistant bacterial superinfection, and a second patient with L. infantum chagasi relapsed and was retreated with miltefosine. These drugs were reasonably well-tolerated. In this limited case series, alternative non-antimony–based regimens were convenient, safe, and effective.

show abstract

Leishmania Braziliensis: Report of a Pediatric Imported Case With Response to Liposomal Amphotericin B

Cited by 4 publications

References 11 publications

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021—A Comprehensive Review

A Species-Specific Approach to the Use of Non-Antimony Treatments for Cutaneous Leishmaniasis

Contact Info

Product

Resources

About